Skip to main navigation Skip to search Skip to main content

A Phase III, Multi-National, Multi-Site, Double-Blind, Placebo-Controlled, 28 Week Study to Assess the Safety & Efficacy of the Engineered Human Anti-TNFa Antibody, CDP571 (10mg/kg), in Patient With Active Crohn's Disease

  • De Villiers, Willem (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date5/15/01 → 5/15/04